Montelukast Induces Apoptosis-Inducing Factor-Mediated Cell Death of Lung Cancer Cells

• Published in: International journal of molecular sciences 2017-06, Vol.18 (7), p.1353
• Main Authors: Tsai, Ming-Ju, Chang, Wei-An, Tsai, Pei-Hsun, Wu, Cheng-Ying, Ho, Ya-Wen, Yen, Meng-Chi, Lin, Yi-Shiuan, Kuo, Po-Lin, Hsu, Ya-Ling
• Format: Article
• Language: English
• Subjects: Acetates - pharmacology; Active Transport, Cell Nucleus; Animals; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Apoptosis Inducing Factor - metabolism; apoptosis-inducing factor; asthma; Biomarkers; Cell Death - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; cysteinyl leukotriene receptor antagonists; Disease Models, Animal; Humans; Leukotriene Antagonists - pharmacology; lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Models, Biological; montelukast; Protein Transport; Quinolines - pharmacology; Signal Transduction - drug effects; Tumor Burden - drug effects; Xenograft Model Antitumor Assays
• ISSN: 1422-0067; 1422-0067
• DOI: 10.3390/ijms18071353

Developing novel chemo-prevention techniques and advancing treatment are key elements to beating lung cancer, the most common cause of cancer mortality worldwide. Our previous cohort study showed that cysteinyl leukotriene receptor antagonists, mainly montelukast, decreased the lung cancer risk in asthma patients. In the current study, we conducted in vivo and in vitro experiments to demonstrate the inhibiting effect of montelukast on lung cancer and to investigate the underlying mechanisms. Using Lewis lung carcinoma-bearing mice, we showed that feeding montelukast significantly delayed the tumor growth in mice ( < 0.0001). Montelukast inhibited cell proliferation and colony formation and induced the cell death of lung cancer cells. Further investigation showed the down-regulation of B-cell lymphoma 2 (Bcl-2), up-regulation of Bcl-2 homologous antagonist/killer (Bak), and nuclear translocation of apoptosis-inducing factor (AIF) in montelukast-treated lung cancer cells. Montelukast also markedly decreased the phosphorylation of several proteins, such as with no lysine 1 (WNK1), protein kinase B (Akt), extracellular signal-regulated kinase 1/2 (Erk1/2), MAPK/Erk kinase (MEK), and proline-rich Akt substrate of 40-kDa (PRAS40), which might contribute to cell death. In conclusion, montelukast induced lung cancer cell death via the nuclear translocation of AIF. This study confirmed the chemo-preventive effect of montelukast shown in our previous cohort study. The utility of montelukast in cancer prevention and treatment thus deserves further studies.